Buprenorphine
43 NDCs across 12 manufacturers|38 Generic,5 Brand
Buprenorphine is used to treat heroin dependence and pain, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
The brand product was first FDA-approved on Jun 30, 2010, and the first generic was approved Nov 20, 2018. FDA's Orange Book lists 24 AB-rated (therapeutically equivalent) products for this ingredient. In 2024, Medicare Part D spent $185 million on Buprenorphine across 514,000 claims for 104,000 beneficiaries.
Buprenorphine is available as 43 NDCs from 12 manufacturers (38 generic, 5 brand), with NADAC prices from $0.28 to $131.09 per EA — the most expensive product costs about 474× the cheapest. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
43
38G / 5B
Manufacturers
12
competing in market
Price Spread
$0.28 – $131.09
per EA
7d Activity
avg +0.9% WoW · of 43 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Explore this market from other angles
Move from the molecule page into the supplier, class, and trend views that create the strongest internal-link cluster for this market.
Top supplier
Rhodes Pharmaceuticals L.P. manufacturer profile
Open the supplier page for the manufacturer with the strongest footprint in this market.
Lead class
Partial Opioid Agonist class view
See how this market rolls up into the broader therapeutic class and compare other drugs in the same bucket.
Trend hub
Latest market trends
Move from this single molecule into the current cross-market mover and volatility view.
Guide
How to interpret NADAC
Review the benchmark methodology behind the prices and spreads shown on this market page.
Manufacturer Breakdown
12 manufacturers producing BUPRENORPHINE
Frequently Asked Questions
What is Buprenorphine used to treat?
Buprenorphine is used to treat heroin dependence and pain, per the National Library of Medicine's MED-RT classification.
When did Buprenorphine become available as a generic?
FDA approved the first generic Buprenorphine (ANDA) on Nov 20, 2018. The Orange Book currently lists 24 AB-rated products for this ingredient, meaning FDA considers them therapeutically equivalent to the brand.
How much does Medicare spend on Buprenorphine?
In 2024, Medicare Part D spent $185 million on Buprenorphine across 514,000 claims for 104,000 beneficiaries.
How many Buprenorphine products are on the market?
The Buprenorphine drug market contains 43 NDCs from 12 manufacturers — 38 generic and 5 brand products.
What is the price range for Buprenorphine?
NADAC reference prices for Buprenorphine range from $0.2768 to $131.0939 per EA — the most expensive product costs about 474× the cheapest.
Is generic Buprenorphine cheaper than brand?
The average generic NADAC for Buprenorphine is $26.0815 per EA, versus $89.4010 for brand-labeled products — brand versions average about 3.4× the generic price.
Which manufacturers make Buprenorphine?
12 manufacturers list Buprenorphine in NADAC. Ranked by number of NDCs, the largest are Rhodes Pharmaceuticals L.P. (7), Purdue Pharma LP (5), Ingenus Pharmaceuticals LLC (5), Teva Pharmaceuticals USA Inc. (5), Amneal Pharmaceuticals NY LLC (5).
How has the price of Buprenorphine changed recently?
Over the past 7 days, 26 Buprenorphine NDCs rose and 13 fell, with a market-wide average change of +0.9%.